Cargando…

Phosphodiesterase Type 5 (PDE5) Inhibitors Sensitize Topoisomerase II Inhibitors in Killing Prostate Cancer Through PDE5-Independent Impairment of HR and NHEJ DNA Repair Systems

Human castration-resistant prostate cancer (CRPC) is a significant target of clinical research. The use of DNA-damaging agents has a long history in cancer chemotherapy but is limited by their toxicities. The combination with a safer drug can be a strategy in reducing dosage and toxicity while incre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chang, Jo-Fan, Hsu, Jui-Ling, Sheng, Yi-Hua, Leu, Wohn-Jenn, Yu, Chia-Chun, Chan, She-Hung, Chan, Mei-Ling, Hsu, Lih-Ching, Liu, Shih-Ping, Guh, Jih-Hwa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6344441/ https://www.ncbi.nlm.nih.gov/pubmed/30705876 http://dx.doi.org/10.3389/fonc.2018.00681

Ejemplares similares

Phosphodiesterase Type 5 Inhibitors Synergize Vincristine in Killing Castration-Resistant Prostate Cancer Through Amplifying Mitotic Arrest Signaling
por: Hsu, Jui-Ling, et al.
Publicado: (2020)

Determination of Phosphodiesterase Type-5 Inhibitors (PDE-5) in Dietary Supplements
por: Gheorghiu, Oana Ramona Cătălina, et al.
Publicado: (2023)

Reversal of neurobehavioral social deficits in dystrophic mice using inhibitors of phosphodiesterases PDE5A and PDE9A
por: Alexander, M S, et al.
Publicado: (2016)

Meta-Analysis of the Association Between Phosphodiesterase Inhibitors (PDE5Is) and Risk of Melanoma
por: Loeb, Stacy, et al.
Publicado: (2017)

Acute effects of phosphodiesterase 5 (PDE5) inhibition, ANP and NO on epididymal contractility are preserved despite chronic PDE5 exposure
por: Mietens, Andrea, et al.
Publicado: (2011)

Phosphodiesterase (PDE)-4 Inhibitors and COPD Correlation with Cancer
por: Organtzis, John, et al.
Publicado: (2014)

Phosphodiesterase 5 (PDE-5) inhibitors (sildenafil, tadalafil, and vardenafil) effects on esophageal motility: a systematic review
por: Shafiee, Arman, et al.
Publicado: (2023)

Role of Phosphodiesterase 7 (PDE7) in T Cell Activity. Effects of Selective PDE7 Inhibitors and Dual PDE4/7 Inhibitors on T Cell Functions
por: Szczypka, Marianna
Publicado: (2020)

The efficacy of PDE5 inhibitors in diabetic patients
por: Swiecicka, Agnieszka
Publicado: (2022)

PDE5 inhibitor drugs for use in dementia
por: Hainsworth, Atticus H., et al.
Publicado: (2023)

Calcium/Calpain mediated regulation of cyclic nucleotide phosphodiesterases, PDE3A and PDE5, in human platelets
por: Rybalkina, Irina G, et al.
Publicado: (2011)

Effect of phosphodiesterase-5 inhibitors (PDE5is) on the treatment of male infertility: A protocol for systematic review and meta-analysis
por: Dong, Liang, et al.
Publicado: (2019)

Rapid Screening and Quantitative Determination of Illegal Phosphodiesterase Type 5 Inhibitors (PDE-5i) in Herbal Dietary Supplements
por: Nguyen, Thi Oanh, et al.
Publicado: (2021)

Investigation of PDE5/PDE6 and PDE5/PDE11 selective potent tadalafil-like PDE5 inhibitors using combination of molecular modeling approaches, molecular fingerprint-based virtual screening protocols and structure-based pharmacophore development
por: Kayık, Gülru, et al.
Publicado: (2017)

Central serous chorioretinopathy treatment with a systemic PDE5 and PDE6 inhibitor (sildenafil)
por: Coleman, D. Jackson, et al.
Publicado: (2020)

Treatment Strategy for Non-Responders to PDE5 Inhibitors
por: Park, Nam Cheol, et al.
Publicado: (2013)

AB041. Evolution of PDE5 inhibitors in Korea
por: Moon, Du Geon
Publicado: (2015)

PDE5 inhibitors enhance the lethality of [pemetrexed + sorafenib]
por: Booth, Laurence, et al.
Publicado: (2017)

Identification of cytosolic phosphodiesterases in the erythrocyte: A possible role for PDE5
por: Adderley, Shaquria P., et al.
Publicado: (2011)

Type 5 phosphodiesterase (PDE5) and the vascular tree: From embryogenesis to aging and disease
por: Cesarini, Valeriana, et al.
Publicado: (2020)

The Combination of a Novel GLUT1 Inhibitor and Cisplatin Synergistically Inhibits Breast Cancer Cell Growth By Enhancing the DNA Damaging Effect and Modulating the Akt/mTOR and MAPK Signaling Pathways
por: Weng, Hao-Cheng, et al.
Publicado: (2022)

Repurposing of nitroxoline as a potential anticancer agent against human prostate cancer – a crucial role on AMPK/mTOR signaling pathway and the interplay with Chk2 activation
por: Chang, Wei-Ling, et al.
Publicado: (2015)

Reevesioside A, a Cardenolide Glycoside, Induces Anticancer Activity against Human Hormone-Refractory Prostate Cancers through Suppression of c-myc Expression and Induction of G1 Arrest of the Cell Cycle
por: Leu, Wohn-Jenn, et al.
Publicado: (2014)

Inhaled Phosphodiesterase 4 (PDE4) Inhibitors for Inflammatory Respiratory Diseases
por: Phillips, Jonathan E.
Publicado: (2020)

Treatment of Experimental Autoimmune Encephalomyelitis with an Inhibitor of Phosphodiesterase-8 (PDE8)
por: Basole, Chaitali P., et al.
Publicado: (2022)

Mechanistic Study of Triazole Based Aminodiol Derivatives in Leukemic Cells—Crosstalk between Mitochondrial Stress-Involved Apoptosis and Autophagy
por: Chan, She-Hung, et al.
Publicado: (2020)

Effect of Phosphodiesterase-5 (PDE-5) Inhibitors on Clinical Outcomes in Patients With Pulmonary Hypertension: A Meta-Analysis of Randomized Control Trials
por: Karedath, Jithin, et al.
Publicado: (2023)

PDE5 Inhibitors as Potential Tools in the Treatment of Cystic Fibrosis
por: Noel, Sabrina, et al.
Publicado: (2012)

Using PDE5 inhibitors for the prevention and treatment of colorectal cancer
por: Browning, Darren D
Publicado: (2015)

Comparative dissolution study on counterfeit medicines of PDE-5 inhibitors
por: Deconinck, E., et al.
Publicado: (2014)

Impact of phosphodiesterases PDE3 and PDE4 on 5-hydroxytryptamine receptor4-mediated increase of cAMP in human atrial fibrillation
por: Dolce, Bernardo, et al.
Publicado: (2020)

Para-Toluenesulfonamide Induces Anti-tumor Activity Through Akt-Dependent and -Independent mTOR/p70S6K Pathway: Roles of Lipid Raft and Cholesterol Contents
por: Hsu, Jui-Ling, et al.
Publicado: (2018)

Autophagic Activation and Decrease of Plasma Membrane Cholesterol Contribute to Anticancer Activities in Non-Small Cell Lung Cancer
por: Hsu, Jui-Ling, et al.
Publicado: (2021)

Development of a New Radiofluorinated Quinoline Analog for PET Imaging of Phosphodiesterase 5 (PDE5) in Brain
por: Liu, Jianrong, et al.
Publicado: (2016)

Phosphodiesterase 5 (PDE5) Is Highly Expressed in Cancer-Associated Fibroblasts and Enhances Breast Tumor Progression
por: Catalano, Stefania, et al.
Publicado: (2019)

On the Viability of Tadalafil-Based (18)F-Radiotracers for In Vivo Phosphodiesterase 5 (PDE5) PET Imaging
por: Bailey, Justin J., et al.
Publicado: (2021)

Effects of the Phosphodiesterase-5 (PDE-5) Inhibitors, Avanafil and Zaprinast, on Bone Remodeling and Oxidative Damage in a Rat Model of Glucocorticoid-Induced Osteoporosis
por: Huyut, Zübeyir, et al.
Publicado: (2018)

Scaffold Repurposing Reveals New Nanomolar Phosphodiesterase Type 5 (PDE5) Inhibitors Based on Pyridopyrazinone Scaffold: Investigation of In Vitro and In Silico Properties
por: Amin, Kamelia M., et al.
Publicado: (2022)

Dr. Bang-Ping Jiann: PDE5 inhibitors in erectile dysfunction
por: Gao, Lucine M.
Publicado: (2016)

PDE5 inhibitor protects the mitochondrial function of hypoxic myocardial cells
por: Jia, Haiyan, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_3bhh4uippoktu2gcf7u51u9j6m